RAAV with chemically modified capsid

US11865185B2 · kind B2 · utility

Assignees

• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• NANTES UNIVERSITE · FR
• CENTRE HOSPITALIER ET UNIVERSITAIRE DE BREST · FR

Inventors

• Mathieu Mevel · Nantes, FR
• David Deniaud · Nantes, FR
• Eduard Ayuso · Nantes, FR

Key dates

• Filing date: Jun 9, 2017
• Grant date: Jan 9, 2024
• Expiry date: May 9, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2810/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.